Statins Inhibit Inflammation Within Prostate Tumors

Feb 18, 2010

(PhysOrg.com) -- Patients with prostate cancer who regularly use statins to lower their cholesterol may be enjoying a secondary benefit from the drugs: A new study from Duke University Medical Center shows that statins significantly lower the degree of inflammation within prostate tumors. The response may, in part, explain why men on statins have a lower risk of disease progression.

Previous studies have shown that reduce systemic , but the Duke researchers were interested in finding out if the drugs reduced inflammation inside tumors, so-called intra-tumoral inflammation, that is believed to contribute to cancer recurrence after surgery.

“We found that preoperative statin use was associated with a 69 percent lower risk of intra-tumoral inflammation," said Lionel Bañez, M.D., an assistant professor of surgery and at Duke and the lead author of the study. "We also discovered a trend suggesting greater risk-reduction with higher doses of the drugs.”

The study appears online in the journal Cancer Epidemiology, Biomarkers & Prevention.

Researchers examined tissue samples of tumors from 236 men undergoing surgery for at the Durham VA Medical Center. Researchers identified the samples as coming from statin-users or non-users, tracked the dose and frequency among the users, and graded the degree of inflammation in the tissue samples as absent, mild, or marked.

They found that 16 percent of the patients (37) took statins during the year prior to surgery. Most (92 percent) were on simvastatin. Eighty-two percent of the patients had inflammatory cells in their prostate tumors, with roughly one-third registering marked tumor inflammation.

After taking into consideration factors such as age, race, body mass index and other clinical variables, investigators found that statin use was associated with reduced inflammation within the tumors. They also found that inflammation was more likely among older patients with more advanced cancers and who had experienced a longer time from biopsy to surgery.

“Increasing evidence suggests that statins may reduce risk of prostate cancer progression, and some studies have even suggested that widespread statin use over the past 15 year has contributed to a decline in prostate cancer mortality,” says Bañez.

So should all prostate cancer patients be on a statin? “No -- or at least not yet.” says Stephen Freedland, M.D., associate professor of urology and pathology in the Duke Prostate Center at Duke University and the senior author of the study. “More studies have to be done before such a recommendation can be made. However, men taking statins for heart health may already be enjoying a beneficial side effect against prostate cancer.”

“If these findings are validated in additional studies, it would support the hypothesis that statins delay prostate cancer progression, in part, by reducing inflammation inside the tumor,” Bañez said.

Explore further: New study helps to explain why breast cancer often spreads to the lung

add to favorites email to friend print save as pdf

Related Stories

Statins alter prostate cancer patients' PSA levels

Apr 28, 2009

Beyond lowering cholesterol, statin medications have been found to have numerous other health benefits, including lowering a healthy man's risk of developing advanced prostate cancer, as well as lowering his prostate-specific ...

Recommended for you

US OKs first-ever DNA alternative to Pap smear (Update 2)

6 hours ago

U.S. government health regulators have cleared a genetic test from Roche as a first-choice screening option for cervical cancer. It was a role previously reserved for the Pap smear, the decades-old mainstay of women's health.

New breast cancer imaging method promising

12 hours ago

The new PAMmography method for imaging breast cancer developed by the University of Twente's MIRA research institute and the Medisch Spectrum Twente hospital appears to be a promising new method that could ...

Palliation is rarely a topic in studies on advanced cancer

12 hours ago

End-of-life aspects, the corresponding terminology, and the relevance of palliation in advanced cancer are often not considered in publications on randomized controlled trials (RCTs). This is the result of an analysis by ...

User comments : 0

More news stories

Genetic code of the deadly tsetse fly unraveled

Mining the genome of the disease-transmitting tsetse fly, researchers have revealed the genetic adaptions that allow it to have such unique biology and transmit disease to both humans and animals.